Citations

Showing 10 of 108048 citations.

Antibody-Targeted Chemotherapy for the Treatment of Melanoma
Nevala, Wendy K. , Buhrow, Sarah A. , Knauer, Daniel J., Atanasova, Elena, Reid, Joel M. , Atanasova, Elena A, Markovic, Svetomir N.

Mayo Clinic

Cancer Research | April 29, 2016 | Volume: 76 | Issue: 13 | Pages: 3954-3964

10.1158/0008-5472.can-15-3131 | PMID 27197186 Get It

Abstract Antibody-directed chemotherapy (ADC) offers an advantage over conventional chemotherapy because it provides antibody-directed targeting, with resultant improvement in therapeutic efficacy and reduced toxicity. Despite extensive research, with notable exceptions, broad clinical application of ADC remains elusive; major hurdles include the instability of antibody–chemotherapy linkers and reduced tumor toxicity of the chemotherapy when bound to the antibody. To address these challenges, we have developed a platform technology that utilizes the nab-paclitaxel formulation of paclitaxel, Abraxane, in which hydrophobic paclitaxel is suspended in 130-nm albumin nanoparticles and thus made water-soluble. We have developed a method to noncovalently coat the Abraxane nanoparticle with recombinant mAbs (anti-VEGF, bevacizumab) and guide Abraxane delivery into tumors in a preclinical model of human A375 melanoma. Here, we define the binding characteristics of bevacizumab and Abraxane, demonstrate that the chemotherapy agent retains its cytotoxic effect, while the antibody maintains the ability to bind its ligand when the two are present in a single nanoparticle (AB160), and show that the nanoparticle yields improved antitumor efficacy in a preclinical human melanoma xenograft model. Further data suggest that numerous therapeutic monoclonal IgG1 antibodies may be utilized in this platform, which has implications for many solid and hematologic malignancies. Cancer Res; 76(13); 3954–64. ©2016 AACR.
AOSSM Early Sport Specialization Consensus Statement
LaPrade, Robert F. , Agel, Julie , Brenner, Joel S. , Cordasco, Frank A. , Feeley, Brian T. , Gould, Daniel , Hainline, Brian , Hewett, Timothy E. , Jayanthi, Neeru , Myer, Gregory D. , Nissen, Carl W. , Provencher, Matthew T. , Hewett, Timothy, Baker, Joseph R. , Cote, Jean Maxime , Engebretsen, Lars , Feeley, Brian T. , Kocher, Mininder Singh , Philippon, Marc J. , Myer, Gregory D , LaPrade, Robert F

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 29, 2016 | Volume: 4 | Issue: 4 | Pages: No page available

10.1177/2325967116644241 | PMID 27169132 Get It

Background: Early sport specialization is not a requirement for success at the highest levels of competition and is believed to be unhealthy physically and mentally for young athletes. It also discourages unstructured free play, which has many benefits. Purpose: To review the available evidence on early sports specialization and identify areas where scientific data are lacking. Study Design: Think tank, roundtable discussion. Results: The primary outcome of this think tank was that there is no evidence that young children will benefit from early sport specialization in the majority of sports. They are subject to overuse injury and burnout from concentrated activity. Early multisport participation will not deter young athletes from long-term competitive athletic success. Conclusion: Youth advocates, parents, clinicians, and coaches need to work together with the sport governing bodies to ensure healthy environments for play and competition that do not create long-term health issues yet support athletic competition at the highest level desired.
Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Roife, David , Lv, Hailong , Ling, Jianhua , Perez, Mayrim V. Rios , Li, Xinqun, Dai, Bingbing , Pratt, Michael, Truty, Mark J. , Thomas, Ryan M. , Chiao, Paul J. , Katz, Matthew H. G. , Fleming, Jason B. , Kang, Ya’an , Lee, Yeon‐Ju , Suzuki, Rei , Chatterjee, Deyali , Wang, Huamin , Wang, Yu , Koay, Eugene J. , Katz, Matthew H G

Mayo Clinic

Clinical Cancer Research | April 29, 2016 | Volume: 22 | Issue: 19 | Pages: 4934-4946

10.1158/1078-0432.ccr-15-2780 | PMID 27126993 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor is characterized by dense composition of cancer cells, stromal cells, and extracellular matrix (ECM) composed largely of collagen. Within the PDAC tumor microenvironment, activated pancreatic stellate cells (PSC) are the dominant stromal cell type and responsible for collagen deposition. Lumican is a secreted proteoglycan that regulates collagen fibril assembly. We have previously identified that the presence of lumican in the ECM surrounding PDAC cells is associated with improved patient outcome after multimodal therapy and surgical removal of localized PDAC. Experimental Design: Lumican expression in PDAC from 27 patients was determined by IHC and quantitatively analyzed for colocalization with PSCs. In vitro studies examined the molecular mechanisms of lumican transcription and secretion from PSCs (HPSCs and HPaSteC), and cell adhesion and migration assays examined the effect of lumican on PSCs in a collagen-rich environment. Results: Here we identify PSCs as a significant source of extracellular lumican production through quantitative IHC analysis. We demonstrate that the cytokine, TGF-β, negatively regulates lumican gene transcription within HPSCs through its canonical signaling pathway and binding of SMAD4 to novel SBEs identified within the promoter region. In addition, we found that the ability of HPSCs to produce and secrete extracellular lumican significantly enhances HPSCs adhesion and mobility on collagen. Conclusions: Our results demonstrate that activated pancreatic stellate cells within PDAC secrete lumican under the negative control of TGF-β; once secreted, the extracellular lumican enhances stellate cell adhesion and mobility in a collagen-rich environment. Clin Cancer Res; 22(19); 4934–46. ©2016 AACR.
Commentary
Drake, Matthew T.

Mayo Clinic

Clinical Chemistry | April 28, 2016 | Volume: 62 | Issue: 5 | Pages: 687-688

10.1373/clinchem.2015.248757 | PMID 27127242 Get It

Sulfate transporters involved in sulfate secretion in the kidney are localized in the renal proximal tubule II of the elephant fish (Callorhinchus milii)
Hasegawa, Kumi , Kato, Akira , Watanabe, Taro , Takagi, Wataru , Romero, Michael F. , Toop, Tes, Hyodo, Susumu , Bell, Justin D. , Donald, John Alexander , Romero, Michael F , Kato, Akira

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | April 28, 2016 | Volume: 311 | Issue: 1 | Pages: R66-R78

10.1152/ajpregu.00477.2015 | PMID 27122370 Get It

Most vertebrates, including cartilaginous fishes, maintain their plasma SO42−concentration ([SO42−]) within a narrow range of 0.2–1 mM. As seawater has a [SO42−] about 40 times higher than that of the plasma, SO42−excretion is the major role of kidneys in marine teleost fishes. It has been suggested that cartilaginous fishes also excrete excess SO42−via the kidney. However, little is known about the underlying mechanisms for SO42−transport in cartilaginous fish, largely due to the extraordinarily elaborate four-loop configuration of the nephron, which consists of at least 10 morphologically distinguishable segments. In the present study, we determined cDNA sequences from the kidney of holocephalan elephant fish ( Callorhinchus milii) that encoded solute carrier family 26 member 1 (Slc26a1) and member 6 (Slc26a6), which are SO42−transporters that are expressed in mammalian and teleost kidneys. Elephant fish Slc26a1 (cmSlc26a1) and cmSlc26a6 mRNAs were coexpressed in the proximal II (PII) segment of the nephron, which comprises the second loop in the sinus zone. Functional analyses using Xenopus oocytes and the results of immunohistochemistry revealed that cmSlc26a1 is a basolaterally located electroneutral SO42−transporter, while cmSlc26a6 is an apically located, electrogenic Cl−/SO42−exchanger. In addition, we found that both cmSlc26a1 and cmSlc26a6 were abundantly expressed in the kidney of embryos; SO42−was concentrated in a bladder-like structure of elephant fish embryos. Our results demonstrated that the PII segment of the nephron contributes to the secretion of excess SO42−by the kidney of elephant fish. Possible mechanisms for SO42−secretion in the PII segment are discussed.
Hypertrophic Cardiomyopathy—One Case per Year?
Ommen, Steve R. , Nishimura, Rick A.

Mayo Clinic

JAMA Cardiology | April 28, 2016 | Volume: 1 | Issue: 3 | Pages: 333

10.1001/jamacardio.2016.0277 | PMID 27438115 Get It

Education on, Exposure to, and Management of Vascular Anomalies During Otolaryngology Residency and Pediatric Otolaryngology Fellowship
Jabbour, Noel , Balakrishnan, Karthik , Darrow, David H., Elluru, Ravindhra G., Grimmer, J. Fredrik , Richter, Gresham T. , Shin, Jennifer J. , Chun, Robert H. , Bauman, Nancy M. , Perkins, Jonathan A. , Balakrishnan, Karthik

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 28, 2016 | Volume: 142 | Issue: 7 | Pages: 648

10.1001/jamaoto.2016.0605 | PMID 27124736 Get It

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
McCall, Andrew N., Ingimarsson, Johann P. , Morrisson, Griffin T., Hook, C. Christopher , Krambeck, Amy E. , Hook, Christopher C.

Mayo Clinic

Journal of Endourology Case Reports | April 28, 2016 | Volume: 2 | Issue: 1 | Pages: 81-83

10.1089/cren.2016.0048 | PMID 27579425 Get It

Abstract Background: Percutaneous nephrolithotomy (PCNL) for large stone burden can be problematic in patients with significant risk of bleeding complications, specifically thrombocytopenia. This report demonstrates effective correction of two patients' thrombocytopenia, subsequently leading to removal of large stone burden through PCNL. Case Presentation: We present two Middle Eastern patients who presented with medical histories significant for thrombocytopenia, secondary to splenomegaly and hepatic vein thrombosis, and large volume nephrolithiasis. Patient 1 is a 65-year-old female with a right 5 cm stone and a platelet count of 34,000. Patient 2 is a 45-year-old female with a 3 cm left staghorn stone and a platelet count of 44,000. After consultation with hematology, both underwent therapy with prednisone and intravenous immunoglobulin without improvement in their platelet count. They then received 3 μg/kg/dose of romiplostim weekly that improved their platelet counts to 133,000 and 195,000 in 2 weeks, respectively. Patient 1's PCNL was completed in a single-stage procedure with stone-free status shown on CT postoperative day 1. Patient 2 underwent PCNL and a secondary ureteroscopy for residual stone fragments on postoperative day 2. Both patients experienced no complication during the procedure, hospital stay, or postoperative course. Both continued romiplostim for 20 days postoperatively with platelet levels returning to their baseline range after 1 month. Conclusion: In the appropriately selected patient, romiplostim can correct thrombocytopenia enough to safely and effectively perform PCNL in patients with underlying hematologic disorders. Close coordination between urology and hematology is imperative to ensure an effective outcome in this challenging patient population.
Faculty Opinions recommendation of Novel intragastric trocar placed by PEG technique permits endolumenal use of rigid instruments to simplify complex endoscopic procedures.
Song, Louis M. Wong Kee

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 28, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726308870.793517356 Get It

Elementary School–Based Obesity Intervention Using an Educational Curriculum
Lynch, Brian , Gentile, Natalie, Maxson, Julie, Quigg, Stephanie, Swenson, L, Kaufman, Tara K. , Lynch, Brian A, Swenson, Laura, Kaufman, Tara

Mayo Clinic

Journal of Primary Care & Community Health | April 28, 2016 | Volume: 7 | Issue: 4 | Pages: 265-271

10.1177/2150131916644888 | PMID 27121724 Get It

Background: Pediatric obesity is a significant public health problem with a prevalence of 16.9% among US children. School-based obesity interventions show promise for reducing adiposity in elementary age children. This pilot study evaluated the impact of the Let’s Go! 5-2-1-0 pediatric obesity intervention program in an elementary school setting. Methods: This was a cluster randomized controlled field trial comprising 8 classrooms of second- and third-grade children. The impact of implementation of a standardized 5-2-1-0 curriculum was evaluated in the classrooms by looking at health behavior (self-reported fruit and vegetable and sugar-containing beverage intake, and screen time), physical activity (steps measured by pedometer), and body mass index (BMI). Half of the classrooms were given 5-2-1-0 teaching over a 4-month period. Results: There was no statistical difference in improvement of healthy habits, BMI, or physical activity in the intervention group compared with the control group. Conclusions: The 5-2-1-0 intervention used in this study was feasible. There was no significant change in healthy habits, likely due to the small number of participants in the study. The intervention and control sites were in different classrooms and there could be factors such as teacher enthusiasm, socioeconomic factors, and individual traits affecting habits. Future studies could use pre- and post-intervention quizzes to assess healthy habits knowledge retention, involving the environments the child participates in outside of school, using research-grade pedometers or accelerometers for measuring activity data collection, and recruiting larger samples to ensure adequate statistical power.